AI주식인사이트AI Stock Insight
B

셀레믹스

331920KOSDAQ

64.8 / 100

Reference Date: 2026-09-08

Financial Score15.5 / 40
News Sentiment21.3 / 25
Momentum18.0 / 20
Disclosure10.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Surged 39.3% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

Cellomics is a company specializing in DNA sequencing and molecular cloning technologies based on molecular biology, utilizing its innovative MSSIC (Massively Separated and Sequence Identified Cloning) technology to enable low-cost, high-throughput analysis. The company offers key products such as Target Capture kits, immune repertoire analysis solutions, and next-generation sequencing solutions, which are widely used in healthcare, pharmaceuticals, agriculture, and other fields.

Number of Employees

41people

Average Salary

60.3M KRW

Score Calculation Basis

Detailed Financial Score

PER
—Industry Average 15.004.0Point
PBR
6.93Industry Average 1.200.0Point

5.8x industry avg (risky)

ROE
-16.08Industry Average 8.000.0Point

Well below industry avg

Debt Ratio
0.48Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~20253.5 / 10 points
Revenue Growth Rate
0.0 / 3

Avg ▼6.0% (2-year basis)

Operating Profit Growth Rate
0.5 / 3

Avg ▼3.8% (2-year basis)

ROE Trend
3.0 / 4

Avg ROE 6.1% (improving, 3yr)

Detailed News Sentiment

1 totalPositive 1Neutral 0Negative 0Average Sentiment Score 85

Detailed Momentum

52-week position6.0Point

52w upper range (74%)

Current 14,260Won52-week high 18,20052-week low 2,580
1-month return6.0Point

1m +39.26% (strong rise)

Volume trend6.0Point

Volume surge

Detailed Disclosure

5 totalPositive 0Neutral 5Negative 0
  • Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-09-03
  • Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-09-02
  • Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-09-02
  • Neutral투자판단관련주요경영사항 (라이선스 및 공급계약 체결)2026-09-01
  • Neutral반기보고서 (2026.06)2026-08-14